Neurocrine Biosciences Inc
NASDAQ:NBIX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111.62
153.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Total Current Assets
Neurocrine Biosciences Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Total Current Assets
$1.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
26%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$27.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$13.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$26.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$9.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$19.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
Neurocrine Biosciences Inc
Glance View
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
See Also
What is Neurocrine Biosciences Inc's Total Current Assets?
Total Current Assets
1.9B
USD
Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Total Current Assets amounts to 1.9B USD.
What is Neurocrine Biosciences Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
26%
Over the last year, the Total Current Assets growth was 14%. The average annual Total Current Assets growth rates for Neurocrine Biosciences Inc have been 23% over the past three years , 18% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
